Serotonergic neurotoxic thioether metabolites of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): synthesis, isolation, and characterization of diastereoisomers.

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a synthetic recreational drug of abuse that produces long-term toxicity associated with the degeneration of serotonergic nerve terminals. In various animal models, direct administration of MDMA into the brain fails to reproduce the serotonergic neurotoxicity, implying a requirement for the systemic metabolism and bioactivation of MDMA. Catechol-thioether metabolites of MDMA, formed via oxidation of 3,4-dihydroxymethamphetamine and 3,4-dihydroxyamphetamine (HHMA and HHA) and subsequent conjugation with glutathione (GSH), are selective serotonergic neurotoxicants when administered directly into brain. Moreover, following systemic administration of MDMA, the thioether adducts are present in rat brain dialysate. MDMA contains a stereogenic center and is consumed as a racemate. Interestingly, different pharmacological properties have been attributed to the two enantiomers, (S)-MDMA being the most active in the central nervous system and responsible for the entactogenic effects, and most likely also for the neurodegeneration. The present study focused on the synthesis and stereochemical analysis of the neurotoxic MDMA thioether metabolites, 5-(glutathion-S-yl)-HHMA, 5-(N-acetylcystein-S-yl)-HHMA, 2,5-bis-(glutathion-S-yl)-HHMA, and 2,5-bis-(N-acetylcystein-S-yl)-HHMA. Both enzymatic and electrochemical syntheses were explored, and methodologies for analytical and semipreparative diastereoisomeric separation of MDMA thioether conjugates by HPLC-CEAS and HPLC-UV, respectively, were developed. Synthesis, diastereoisomeric separation, and unequivocal identification of the thioether conjugates of MDMA provide the chemical tools necessary for appropriate toxicological and metabolic studies on MDMA metabolites contributing to its neurotoxicity.

[1]  T. Monks,et al.  Accumulation of Neurotoxic Thioether Metabolites of 3,4-(±)-Methylenedioxymethamphetamine in Rat Brain , 2008, Journal of Pharmacology and Experimental Therapeutics.

[2]  F. García-Cánovas,et al.  Stereospecificity of mushroom tyrosinase immobilized on a chiral and a nonchiral support. , 2007, Journal of agricultural and food chemistry.

[3]  A. Urios,et al.  Bacterial plate assays and electrochemical methods: an efficient tandem for evaluating the ability of catechol-thioether metabolites of MDMA ("ecstasy") to induce toxic effects through redox-cycling. , 2007, Chemical research in toxicology.

[4]  D. Sheehan,et al.  Chemical modification at subunit 1 of rat kidney Alpha class glutathione transferase with 2,3,5,6-tetrachloro-1,4-benzoquinone: close structural connectivity between glutathione conjugation activity and non-substrate ligand binding. , 2006, Biochemical pharmacology.

[5]  R. de la Torre,et al.  Serotonergic Neurotoxic Metabolites of Ecstasy Identified in Rat Brain , 2005, Journal of Pharmacology and Experimental Therapeutics.

[6]  R. de la Torre,et al.  Stereochemical analysis of 3,4-methylenedioxymethamphetamine and its main metabolites in human samples including the catechol-type metabolite (3,4-dihydroxymethamphetamine). , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[7]  C. Marsden,et al.  Synthesis, in vitro formation, and behavioural effects of glutathione regioisomers of alpha-methyldopamine with relevance to MDA and MDMA (ecstasy) , 2003, Brain Research.

[8]  T. Monks,et al.  The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. , 2002, Current drug metabolism.

[9]  R. de la Torre,et al.  Synthesis and capillary electrophoretic analysis of enantiomerically enriched reference standards of MDMA and its main metabolites. , 2002, Bioorganic & medicinal chemistry.

[10]  H. Maurer,et al.  Toxicokinetics of Amphetamines: Metabolism and Toxicokinetic Data of Designer Drugs, Amphetamine, Methamphetamine, and Their N-Alkyl Derivatives , 2002, Therapeutic drug monitoring.

[11]  R. de la Torre,et al.  3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. , 2001, Chemical research in toxicology.

[12]  V. Sánchez,et al.  3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose , 2001, Psychopharmacology.

[13]  K. Kreth,et al.  Identification of the human cytochromes P450 involved in the oxidative metabolism of "Ecstasy"-related designer drugs. , 2000, Biochemical pharmacology.

[14]  Z. Szabo,et al.  Toxicodynamics and long-term toxicity of the recreational drug, 3, 4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'). , 2000, Toxicology letters.

[15]  R. de la Torre,et al.  Non-linear pharmacokinetics of MDMA ('ecstasy') in humans. , 2000, British journal of clinical pharmacology.

[16]  T. Monks,et al.  Glutathione and N-acetylcysteine conjugates of alpha-methyldopamine produce serotonergic neurotoxicity: possible role in methylenedioxyamphetamine-mediated neurotoxicity. , 1999, Chemical research in toxicology.

[17]  P. Milligan,et al.  Stereospecific analysis and enantiomeric disposition of 3, 4-methylenedioxymethamphetamine (Ecstasy) in humans. , 1999, Clinical chemistry.

[18]  M. Colado,et al.  The relationship between the degree of neurodegeneration of rat brain 5-HT nerve terminals and the dose and frequency of administration of MDMA (`ecstasy') , 1998, Neuropharmacology.

[19]  J. Bolton,et al.  Inhibition of glutathione S-transferase activity by the quinoid metabolites of equine estrogens. , 1998, Chemical research in toxicology.

[20]  F. García-Cánovas,et al.  Study of stereospecificity in mushroom tyrosinase. , 1998, The Biochemical journal.

[21]  B. Mannervik,et al.  Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. , 1997, The Biochemical journal.

[22]  R. T. Miller,et al.  Effects of intracerebroventricular administration of 5-(glutathion-S-yl)-alpha-methyldopamine on brain dopamine, serotonin, and norepinephrine concentrations in male Sprague-Dawley rats. , 1996, Chemical research in toxicology.

[23]  R. T. Miller,et al.  Metabolism of 5-(glutathion-S-yl)-alpha-methyldopamine following intracerebroventricular administration to male Sprague-Dawley rats. , 1995, Chemical research in toxicology.

[24]  G. Tucker,et al.  The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6). , 1994, Biochemical pharmacology.

[25]  P. van Bladeren,et al.  Inhibition of human glutathione S-transferases by dopamine, alpha-methyldopa and their 5-S-glutathionyl conjugates. , 1994, Chemico-biological interactions.

[26]  K. Cunningham,et al.  Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA) , 1992, Brain Research Bulletin.

[27]  G. Ricaurte,et al.  Synthesis and neurotoxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedioxy)methamphetamine]. , 1992, Chemical research in toxicology.

[28]  U. McCann,et al.  Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users. , 1991, Journal of clinical psychopharmacology.

[29]  A. Cho,et al.  Transformation of dopamine and alpha-methyldopamine by NG108-15 cells: formation of thiol adducts. , 1991, Chemical research in toxicology.

[30]  P. van Bladeren,et al.  Irreversible inhibition of rat glutathione S-transferase 1-1 by quinones and their glutathione conjugates. Structure-activity relationship and mechanism. , 1991, The Biochemical journal.

[31]  A. Cho,et al.  Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione adduct. , 1990, The Journal of pharmacology and experimental therapeutics.

[32]  R. Foltz,et al.  In vivo and in vitro metabolism of 3,4-(methylenedioxy)methamphetamine in the rat: identification of metabolites using an ion trap detector. , 1988, Chemical research in toxicology.

[33]  C. J. Schmidt,et al.  Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons. , 1988, European journal of pharmacology.

[34]  J. Langston,et al.  Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration , 1988, Brain Research.

[35]  L S Seiden,et al.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. , 1987, The Journal of pharmacology and experimental therapeutics.

[36]  W. Lovenberg,et al.  In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. , 1987, Biochemical pharmacology.

[37]  M. P. Johnson,et al.  Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. , 1986, European journal of pharmacology.

[38]  L. Seiden,et al.  Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. , 1985, Science.

[39]  D. E. Nichols,et al.  Effects of certain hallucinogenic amphetamine analogues on the release of [3H]serotonin from rat brain synaptosomes. , 1982, Journal of medicinal chemistry.

[40]  R. Stitzel,et al.  Alpha-methyldopamine derivatives. Synthesis and pharmacology. , 1974, Journal of medicinal chemistry.